X0306 4 2022-04-30 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001751790 Wolff Stefani C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 0 1 0 0 EVP and COO Common Stock 2022-04-30 4 M 0 962 0.00 A 962 D Common Stock 2022-05-02 4 S 0 330 11.75 D 632 D Restricted Stock Units 0.00 2022-04-30 4 M 0 962 0.00 D Common Stock 962 14430 D The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the vest date. /s/ Christine Ring, as Attorney-in-Fact for Stefani Wolff 2022-05-03